Deutsche Bank Doubles Humana Price Target to $441, Cites 2026 Rebound
HUM•Deutsche Bank upgraded Humana to Buy from Hold, raising its price target to $441 from $235 and projecting 2026 as an earnings bottom with a rebound tied to October’s Medicare Star ratings. Analysts cite improved underwriting discipline, peaking healthcare utilization trends and rebounding margin potential for managed care insurers.
1. Deutsche Bank Upgrade Details
Deutsche Bank raised Humana’s rating from Hold to Buy and lifted its price target to $441 from $235, projecting 2026 as the earnings bottom and rebasing year. The firm highlighted anticipated improvements in Medicare Star ratings as a key catalyst for Humana’s turnaround.
2. Sector Outlook and Margin Recovery
Analysts point to stronger underwriting discipline and disciplined product pricing as drivers for margin recovery across managed care insurers. Peaking healthcare utilization trends are expected to ease cost pressures and support Humana’s profitability in the coming years.
3. Star Ratings Uncertainty
Humana’s rebound hinges on its October 2026 Medicare Star ratings outcome, which will influence payment adjustments and market perception. Any underperformance in Star ratings could delay the projected earnings recovery and affect investor sentiment.
